Utilization of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scale for evaluation of quality of life among cancer patients treated with chemotherapy: A hospital-based observational study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE
    • Publication Information:
      Publication: London : SAGE Publications
      Original Publication: Norwalk, CT : Appleton & Lange, c1995-
    • Subject Terms:
      Quality of Life* ; Neoplasms*/drug therapy ; Neoplasms*/psychology; Humans ; Female ; Middle Aged ; Male ; Surveys and Questionnaires ; Aged ; Adult ; Antineoplastic Agents/therapeutic use ; India ; Tertiary Care Centers
    • Abstract:
      Background: In this new era of cancer management, the quality of life (QOL) is given more importance than the quantity of life. QOL evaluation studies are widely used in oncology to assess the patient's performance in different cancer types and treatment modalities.
      Objective: To evaluate cancer patients' QOL after various chemotherapy cycles.
      Methods: An observational study was performed on cancer patients receiving chemotherapy in the daycare setting of a South Indian Tertiary Care Hospital for 6 months. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire was employed to study the QOL.
      Results: Precisely, 102 patients participated in the study, out of which the majority were in the 51 to 60 age group (24%). Female participants (65%) were more. Functional scale domains especially physical ability ( P  = 0.004), role ( P  = 0.033), and emotional functioning ( P  = 0.01) were significantly decreased in patients treated with 4 to 6 chemotherapy cycles. Cognitive ability ( P  = 0.043) significantly improved in patients treated with more than 6 chemotherapy cycles. Dyspnea ( P  = 0.036) was significantly increased in patients treated with 4 to 6 chemotherapy cycles and decreased significantly with the further addition of chemotherapy cycles.
      Conclusion: Dyspnea is a commonly observed symptom among cancer patients and is often neglected by physicians. Chronic dyspnea can negatively impact a patient's functional ability. Cancer symptoms such as dyspnea should also be given priority and need appropriate treatment. Based on the findings, further interventions can be made to improve the functional ability of cancer patients. Also, studies can be conducted to correlate with cancer rehabilitation programs to improve functional ability and complete the entire chemotherapy cycle.
      Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
    • Contributed Indexing:
      Keywords: EORTC QLQ-C30; dyspnea; functional ability; quality of life; rehabilitation
    • Accession Number:
      0 (Antineoplastic Agents)
    • Publication Date:
      Date Created: 20230804 Date Completed: 20240614 Latest Revision: 20240726
    • Publication Date:
      20240727
    • Accession Number:
      10.1177/10781552231189706
    • Accession Number:
      37537966